Background {#Sec1}
==========

Prostate cancer (PCa) is one of the most common cancers in the world, especially in North America and Western Europe \[[@CR1]\], with over 50% of patients suffering from intermediate- to high-risk localized PCa \[[@CR2], [@CR3]\]. On the basis of the results of previous studies, external-beam radiation therapy (EBRT) combined with androgen deprivation therapy (ADT) is a standard treatment for patients with intermediate- to high-risk PCa \[[@CR4], [@CR5]\]. Compared with a dose of 75.6 to 79.2Gy for low-risk patients, doses up to 81Gy in form of conventional fractionation schedules have been recommended for patients with intermediate- to high-risk PCa \[[@CR6]--[@CR8]\]. However, conventionally fractionated dose escalation protracts treatment time, which could possibly increase side effects and yield lower treatment efficacy.

In ideal conditions, radiotherapy dose fractionation schedules should take into account the sensitivity to radiation of the tumor relative to nearby non-tumor tissues. Accumulating evidence shows that the α/β ratio for PCa is low and range from 0.9 to 2.2 Gy \[[@CR9]\]. Radiobiological theory suggests that hypofractionated radiation schedules applied in fewer fractions and with larger single doses could increase treatment effects \[[@CR10]\]. Further, hypofractionated radiotherapy with single dose≥2.5 Gy per fraction could theoretically maintain high biologically effective doses, while not increasing acute and late adverse events, but efficiently shortening the treatment time. Such outcome would translate into higher treatment capacity and could potentially reduce treatment cost \[[@CR11]\].

The results of treatment after hypofractionated radiotherapy have only been reported from several small randomized trials \[[@CR12], [@CR13]\]. The efficacy and adverse events of hypofractionated radiotherapy seemed to be comparable with conventional schedules in the treatment of intermediate- to high-risk PCa. However, small sample size trials might have biased results, although no significant effect of publication bias was detected. Lastly, we pooled the relevant outcomes of randomized trials and compared the efficacy and adverse events profile of hypofractionated with those of conventional radiotherapy for intermediate- to high-risk localized PCa.

Methods {#Sec2}
=======

Literature search {#Sec3}
-----------------

This meta-analysis was conducted according to Preferred Reporting Items For Systematic Reviews and Meta-analyses guidelines (PRISMA) \[[@CR14]\]. As this meta-analysis was performed based on the published data, ethics committee and/or institutional board approval was not required. Our literature search was performed via Pubmed, Embase and Web of Science databases. The last search was updated to August 2018. The search strategy was: "prostatic neoplasms" (MeSH Terms), "radiotherapy" (MeSH Terms), and "hypofractionated" (All Fields). At the same time, we also checked abstracts published in major academic conferences. The references of studies included were screened to locate potentially eligible articles.

Study selection {#Sec4}
---------------

The selected studies should meet the following eligibility criteria: (1) comparison of the use of hypofractionated (ie, dose per fraction range from 2.4--4.0 Gy) with that of conventional radiotherapy (1.8--2.0 Gy per fraction) for intermediate- to high-risk PCa; (2) clear description of applied case selection criteria; (3) reported data allows calculating hazard ratio (HR) or risk ratio (RR) with its corresponding 95% confidence interval (CI) or alternatively these could be computed according to Tierney's method \[[@CR15]\]; (4) published as full-text articles; (5) published in English language. The exclusion criteria were: (1) patients have received previous pelvic radiotherapy or radical prostatectomy; (2) animal studies; (4) letters, conference abstracts or review articles.

Data extraction {#Sec5}
---------------

Two investigators (W.G. And L.X.) independently extracted the following data from the eligible studies using a predefined protocol: name of the first author, country, sample size, radiotherapy methods, radiotherapy schedule, androgen deprivation therapy (ADT) and clinical outcome measures. Discrepancies between the two reviewers were settled by the third investigator (Y.C.S. and X.Y.H.).

Statistical analysis {#Sec6}
--------------------

HRs and RRs with 95% CIs for clinical outcome measures were directly obtained from each study if available or were calculated from raw data using the method reported by Tierney et al. \[[@CR15]\]. The Cochran's Q test and Higgins I-squared statistic were used to evaluate the heterogeneity of pooled results. If I^2^ \>50% and P for heterogeneity \< 0.1, which show significant heterogeneity, the random-effect model was used; otherwise, the fixed-effects model was conducted. Sensitivity analyses were performed to evaluate the impact of individual studies on the overall estimate. Begg's funnel plot was assessed to find publication bias. All data were analyzed through the STATA 12.0 software (Stata Corp, College Station, TX, USA). A *p*-value \< 0.05 was considered as statistically significant.

Results {#Sec7}
=======

Study characteristics {#Sec8}
---------------------

A total of 416 articles were initially identified. Duplicates were removed and 364 articles remained. A total of 316 records were excluded after titles and abstracts screening. Full texts and data integrity were then reviewed, and another 36 papers were excluded. In the end, 12 studies (6 cohorts) \[[@CR12], [@CR13], [@CR16]--[@CR25]\] were included in the final meta-analysis. Our article selection process is shown in Fig. [1](#Fig1){ref-type="fig"}. All the studies included were randomized controlled trials. Publication years of the records included articles from 2006 to 2017. A total of 2827 patients consisting of 1444 cases treated with hypofractionated radiotherapy and 1383 cases treated with conventional radiotherapy from 6 cohorts were included for this meta-analysis. All patients suffered from intermediate- to high-risk PCa and did not receive previous pelvic radiotherapy or radical prostatectomy. Three cohorts were from Italy, one from the USA and one from Netherlands. The latest study was conducted in 27 centers (14 in Canada, 12 in Australia, and one in France). The detailed characteristics of the selected studies are shown in Table [1](#Tab1){ref-type="table"}. Fig. 1Flow chart of the included trials Table 1Study characteristicsStudyYearCountrynTNM or risk groupRTDesignScheduleADTOutcomesAluwini et al2015--2016Netherlands410T~1b~-T~4~N~X-0~M~X-0~intermediate- to high-riskMost IMRTHypofractionated versus conventional64.6Gy (19 fractions within 6.5wks)YesOS, BFacute and late adverse events41078Gy (39 fractions within 8wks)Arcangeli et al2010--2017Italy83≥T~2c~, Gleason ≥7PSA ≥20ng/mlhigh-risk3D-CRTHypofractionated versus conventional62Gy (20 fractions of 3.1Gy, 5wks)YesOS, BF, PCaSSacute and late adverse events8580Gy (40 fractions of 2Gy, 8wks)Pollack et al2007--2013US154T~1~-T~3~, Gleason ≥5intermediate- to high-riskIMRTHypofractionated versus conventional70.2Gy (26 fractions of 2.7Gy)YesOS, BFlate adverse event15376Gy (38 fractions of 2Gy)Marzi et al2009Italy57≥T~2c~, Gleason7-10PSA\>10ng/mlhigh-risk3D-CRTHypofractionated versus conventional62Gy (20 fractions of 3.1Gy)Yeslate adverse event5780Gy (40 fractions of 2Gy)Strigary et al2009Italy80localized prostate cancer high-risk3D-CRTHypofractionated versus conventional62Gy (20 fractions of 3.1Gy)Yesacute adverse event5256Gy (16 fractions of 3.5Gy)80Gy (40 fractions of 2Gy, 8wks)80Catton et al2017Canada608intermediate-riskIMRTHypofractionated versus conventional60Gy (20 fractions of 3Gy)YesBF, PCaSSacute and late adverse eventsAustraliaFrance59878Gy (39 fractions of 2Gy)*OS* Overall survival, *BF* Biochemical failure, *ADT* Androgen deprivation therapy, *PCaSS* Prostate cancer-specific survival, *IMRT* Intensity-modulated radiation therapy, *3D-CRT* Three-dimensional conformal radiotherapy, *PSA* Prostate-specific antigen

Overall survival, prostate cancer-specific survival and biochemical failure {#Sec9}
---------------------------------------------------------------------------

Because of homogeneous outcomes of the selected studies (I^2^ = 0, *p* = 0.606), the fixed-effect model was applied for the overall survival (OS) rate. Our results showed that hypofractionated radiotherapy was not superior to conventional radiotherapy (HR = 1.12, 95% CI: 0.93--1.35, *p* = 0.219, Fig. [2](#Fig2){ref-type="fig"}a). The hypofractionated radiotherapy and the conventional radiotherapy of patients showed no substantial differences in prostate cancer-specific survival analysis (HR = 1.29, 95% CI: 0.42--3.95, *p* = 0.661) and showed a high level of heterogeneity based on the random effect model (I^2^ = 61.6%, *p* = 0.106, Fig. [2](#Fig2){ref-type="fig"}b). We used a fixed-effect model to analyze biochemical failure (BF) because there was no statistical heterogeneity across studies (I^2^ = 0, *p* = 0.440), and the number of patients who were affected by BF was similar among the two groups (RR = 0.90, 95% CI: 0.76--1.07, *p* = 0.248, Fig. [2](#Fig2){ref-type="fig"}c). Fig. 2Forest plot for overall survival (**a**), prostate cancer-specific survival (**b**) and biochemical failure (**c**)

Acute and late adverse events {#Sec10}
-----------------------------

The incidence of grade 2 or worse acute adverse gastrointestinal events were analyzed by the random effect model due to heterogeneous outcomes (I^2^ = 67.2%, *p* = 0.016) and the pooled data revealed a clear rising trend in the hypofractionated radiotherapy compared with conventional radiotherapy (RR = 1.70, 95% CI: 1.12--2.56, *p* = 0.012, Fig. [3](#Fig3){ref-type="fig"}a). However, acute grade ≥ 3 adverse gastrointestinal events were not significantly different between groups (*p*\>0.05). Acute genitourinary adverse events (grade ≥ 2) were similar among the groups (RR = 1.01, 95% CI: 0.89--1.15, *p* = 0.894, Fig. [3](#Fig3){ref-type="fig"}b) with no heterogeneity (I^2^ = 0, *p* = 0.683). Fig. 3Forest plot for acute adverse gastrointestinal event (**a**), acute genitourinary adverse event (**b**), late adverse gastrointestinal event (**c**) and late adverse genitourinary event (**d**)

Analysis by the fixed-effect model (I^2^ = 0, *p* = 0.826) showed that conventional radiotherapy significantly increased the grade ≥ 2 late gastrointestinal adverse event in comparison with the hypofractionated radiotherapy (RR = 0.75, 95% CI: 0.61--0.91, *p* = 0.003, Fig. [3](#Fig3){ref-type="fig"}c). The grade ≥ 2 late genitourinary adverse event data were similar between the hypofractionated radiotherapy and conventional radiotherapy groups (RR = 0.98, 95% CI: 0.86--1.10, *p* = 0.692, Fig. [3](#Fig3){ref-type="fig"}d) and no heterogeneity was found for this analysis (I^2^ = 0, *p* = 0.496).

Subgroup analysis {#Sec11}
-----------------

When we analyzed the subgroup of patients who received only conventional higher doses of radiotherapy (≥78 Gy) versus hypofractionated radiotherapy, the incidence of grade 2 or worse acute adverse gastrointestinal events were still higher in the hypofractionated radiotherapy (RR = 1.66, 95% CI: 1.05--2.61, *p* = 0.029). However, the other results (OS, BF and genitourinary adverse events etc.) were not significantly different between the two groups (all *p*\>0.05).

Sensitivity analysis and publication bias {#Sec12}
-----------------------------------------

Sensitivity analysis was performed to demonstrate whether the meta-analysis result was robust. The results of sensitivity analysis were shown in Fig. [4](#Fig4){ref-type="fig"}, which revealed that no individual studies affected the pooled HR or RR significantly, showing a statistically stability result. Begg test demonstrated no significant statistical evidence of publication bias (*p*\>0.05), which suggested that this meta-analysis was not significantly affected by publication bias. Fig. 4Sensitivity analysis of late adverse genitourinary event

Discussion {#Sec13}
==========

A large number of clinical studies have suggested that dose escalation is associated with improved biochemical and OS outcomes \[[@CR26]--[@CR29]\]. A study of the National Cancer Data Base showed that dose escalation resulted in an improvement in OS for patients with intermediate- to high-risk PCa \[[@CR30]\]. Kuban et al. \[[@CR29]\] published their dose-escalation study of 301 patients with T~1b~ to T~3~ PCa. Clinical failure or freedom from biochemical was superior for patients treated with 78Gy versus 70Gy (78% vs. 59%, *p* = 0.004), and the patients with initial prostate specific antigen (PSA)\>10 ng/ml (intermediate- to high-risk PCa) had a greater benefit (78% vs. 39%, *p* = 0.001). However, conventionally fractionated dose escalation increased toxicity and overall treatment time. With improved radiotherapy technologies, hypofractionated radiotherapy plays a crucial role in the treatment of intermediate- to high-risk PCa. Several randomized trials have proved that efficacy and adverse events of hypofractionated radiotherapy were similar to conventional radiotherapy in most \[[@CR13], [@CR20]\] but not all trials \[[@CR18]\]. With aims to provide sufficient evidence for clarifying the discrepancies, the present meta-analysis was designed to compare clinical outcomes and adverse events of hypofractionated radiotherapy with conventional radiotherapy for patients with intermediate- to high-risk PCa with the aim to increase the precision of the comparisons and the estimate of treatment benefit.

Overall survival is the most important result for any cancer therapy because it accounts for secondary mortality causes, the interventions used, and all other mortality causes. Given the indolent nature of the progression of prostate cancer, long-term follow-up is of particular importance to assess differences in overall survival \[[@CR31]\]. The median follow-up for the selected studies ranges from 5 to 9 years, and we found that hypofractionated radiotherapy was not superior to conventional radiotherapy. Although hypofractionated radiotherapy did not significantly improve overall survival, it enhanced biological efficacy of delivered radiation dose and reduced overall treatment time, presumably making the treatment more acceptable for patients. Biochemical failure was defined according to the Phoenix definition of nadir PSA plus 2 ng/ml \[[@CR32]\]. Although there was no significant difference in avoiding biochemical failure between the two groups, there was still a trend in favor of hypofractionated radiotherapy. The α/β ratio for PCa is 1.5Gy from the included studies. After further analysis, we found that the biologically effective dose (BED) of hypofractionated radiotherapy was slightly higher compared to conventional radiotherapy. This difference may explain why no significant difference in biochemical failure was detected between groups.

Recently, hypofractionated radiotherapy has been introduced as treatment for prostate cancer. Noteworthy, hypofractionated radiotherapy schedules have a large variability in the treatment regimens, and the data on adverse events are sparse. Thus, we pooled the relevant data and found the incidence of acute adverse gastrointestinal event (grade ≥ 2) was higher in the hypofractionated radiotherapy; conversely, for late grade ≥ 2 gastrointestinal adverse events, a significant increase in the conventional radiotherapy was found. Furthermore, grade ≥ 3 acute gastrointestinal adverse events in the two groups was not significantly different, and grade 2 acute gastrointestinal adverse events were acceptable for patients. The BED for acute gastrointestinal effect for hypofractionated radiotherapy was significantly greater compared to conventional radiotherapy in the included trials evaluated for acute gastrointestinal toxicity (*p\<*0.05). This could be expected to contribute to the increased acute toxicity with hypofractionated radiotherapy. The reduction in late adverse event for hypofractionated radiotherapy is consistent with the linear-quadratic model by Catton et al. \[[@CR25]\] that would predict a lower biologically equivalent dose for normal tissues with an α/β of 3-5Gy. This finding is further supported by the trial conducted by Dearnaley et al. \[[@CR33]\], who reported a lower 5-year incidence of grade ≥ 2 gastrointestinal adverse events for both hypofractionated groups compared to conventional therapy.

Our pooled data showed that Grade ≥ 2 acute and late genitourinary adverse events were not significantly different between the groups. In 2016, another meta-analysis from Cao et al. found similar genitourinary adverse events between hypofractionated and conventional groups \[[@CR34]\]. A long-term late adverse event finding from Arcangeli et al. showed that, a relevant impact did not appear with high-dose fractions and; significant differences were only seen for minor (grade 1), late genitourinary adverse events, namely, for macroscopic hematuria \[[@CR21]\].

Our meta-analysis was the first designed to compare clinical outcomes and adverse events between hypofractionated radiotherapy and conventional radiotherapy for the treatment of intermediate- to high-risk localized PCa. In terms of efficacy and adverse events, a large number of studies had tested hypofractionated radiotherapy and found that effects were compared to conventional radiotherapy in the treatment of low-risk localized PCa \[[@CR35]--[@CR37]\]. Published meta-analyses suggest that hypofractionated radiotherapy could result in comparable therapeutic effects for patients suffering from localized prostate cancer without increasing the rate of acute or late adverse events of the gastrointestinal or genitourinary system \[[@CR38]--[@CR41]\]. Our results are in accordance with these previous findings.

Noteworthy, the current meta-analysis had a number of limitations. First, the patients included in our meta-analysis were all Caucasian ethnicity. Therefore, the conclusions of this study should be treated with caution when applied on other ethnic populations. Second, we failed to analyze the absence of biochemical failure because the reported data was insufficient. Third, the heterogeneity of acute gastrointestinal adverse events was relatively large, which might affect its result.

Conclusion {#Sec14}
==========

In summary, meta-analytical data suggest that the efficacy of hypofractionated radiotherapy is comparable to conventional radiotherapy in the treatment of intermediate- to high-risk localized PCa. Although incidences of acute gastrointestinal adverse events were found higher for patients treated with hypofractionated radiotherapy, hypofractionated radiotherapy was safe with overall acceptable adverse event rates. However, due to the limited sample of trials that informed this meta-analysis, these findings should be utilized cautiously when directed in clinical treatment.
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